Daxas REMS May Be Key To Approval After "Complete Response" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seems more likely to approve the COPD if labeling is restricted to moderate-to-severe patients with chronic bronchitis, but Forest will probably need to show that it can limit use.